Norstella

Eli Lilly Gateway Labs in South San Francisco, California.
#Eli Lilly #GLP-1 #Market reporting #Norstella

New index reveals Eli Lilly as the top ranked company

Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.  The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. The index is… Read More

#Business & Investment #News #Trending News

#AI #Clinical development #Clinical trial #Norstella #Real world data

How AI has revolutionised clinical development

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Suzanne Caruso, President of Strategic Intelligence and Clinical & Regulatory at Norstella. Norstella supports drug developers looking to take their treatments from pipeline to patients, finding solutions to complexities… Read More

#Featured Podcasts #Podcasts

#Big pharma #Biopharmaceuticals #Market reporting #Norstella

Biopharma will be worth $1.6tn in 2028, analysts predict

A new forecast predicts global prescription drug sales to be worth $1.6tn by 2028. Global biopharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, according to the latest World Preview report published by Evaluate. The annual report forecasts that while the industry will have… Read More

#Business & Investment #Market Reports #News #Trends & Analysis

#Citeline #Clinical trials #Mergers and acquisitions #Norstella #Pharma intelligence

Merger creates $5 billion pharma technology company 

Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market.  Norstella now has more than 1,500 employees across its five brands: Evaluate, MMIT, Panalgo, The Dedham Group, and Citeline.  “We believe that patient access starts… Read More

#Business & Investment #News